Source comparison
BPC-157 Sermorelin Protocol: Injury Type Comparison
Tendon strain (acute) 300–500mcg SC near injury site, daily 200mcg SC before sleep, daily 4–6 weeks BPC-157: angiogenesis + collagen synthesis; Sermorelin: systemic IGF-1 elevation Inject BPC-157 within 2cm of strain for maximum VEGF upregulation Ligament spra
This comparison does not assign a generated winner or score.
- Tendon strain (acute)
- 300–500mcg SC near injury site, daily
- 200mcg SC before sleep, daily
- 4–6 weeks
- BPC-157: angiogenesis + collagen synthesis; Sermorelin: systemic IGF-1 elevation
- Inject BPC-157 within 2cm of strain for maximum VEGF upregulation
- Ligament sprain (chronic)
- 400mcg SC near injury site, daily
- 250–300mcg SC before sleep, daily
- 6–8 weeks
- BPC-157: fibroblast migration; Sermorelin: enhanced collagen turnover
- Chronic cases require longer sermorelin exposure for remodelling
- Muscle tear (partial)
- 250–400mcg SC at tear site, daily
- BPC-157: satellite cell activation; Sermorelin: protein synthesis amplification
- Combine with adequate protein intake (1.8–2.2g/kg) for maximal effect
- Post-surgical recovery
- 300mcg SC abdominal, daily
- 250mcg SC before sleep, daily
- BPC-157: wound closure + scar minimisation; Sermorelin: systemic tissue repair
- Abdominal dosing acceptable when surgical site not accessible
- Joint inflammation
- 250–400mcg SC periarticular, daily
- 200–250mcg SC before sleep, daily
- BPC-157: anti-inflammatory via NO pathway; Sermorelin: cartilage repair via IGF-1
- Evidence strongest for knee and shoulder inflammation